Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Net Cash Flow (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Net Cash Flow for 6 consecutive years, with -$10.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 42.43% year-over-year to -$10.3 million, compared with a TTM value of -$29.7 million through Sep 2025, up 51.07%, and an annual FY2024 reading of -$27.7 million, up 49.2% over the prior year.
  • Net Cash Flow was -$10.3 million for Q3 2025 at Barinthus Biotherapeutics, up from -$18.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $113.5 million in Q1 2021 and bottomed at -$20.2 million in Q4 2021.
  • Average Net Cash Flow over 5 years is $1.7 million, with a median of -$11.2 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 8883.03% in 2021, while the deepest fall reached 296.52% in 2021.
  • Year by year, Net Cash Flow stood at -$20.2 million in 2021, then soared by 43.21% to -$11.4 million in 2022, then tumbled by 68.99% to -$19.3 million in 2023, then soared by 170.55% to $13.6 million in 2024, then plummeted by 175.3% to -$10.3 million in 2025.
  • Business Quant data shows Net Cash Flow for BRNS at -$10.3 million in Q3 2025, -$18.1 million in Q2 2025, and -$14.9 million in Q1 2025.